25 July 2023 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has posted results from multiple studies reinforcing Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a range of people with HIV, the company said.

The latest findings include key insights into the treatment of virologically suppressed pregnant women and children two years of age or older (weighing at least 14 kg to less than 25 kg) and positive Week 96 data from the ALLIANCE trial in adults with HIV/hepatitis B coinfection who were initiating therapy.

The data were presented at the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place July 23-26 in Brisbane, Australia.

In an open-label study evaluating the pharmacokinetics, safety, and efficacy of switching to once-daily Biktarvy in virologically suppressed pregnant women with HIV, Biktarvy was generally well tolerated and all participants maintained virologic suppression at delivery (HIV-1 RNA